Synribo for CML

Synribo (injectable) now approved for CML patients with resistance or intolerance to 2 or more TKIs.

Liquid tamoxifen now available

A liquid form of tamoxifen is now available for breast cancer patients who have trouble swallowing tablets. It's called Soltamox Oral Solution, marketed by DARA BioSiences. 

Bosulif now approved in CML

Bosulif (bosutinib) has been recently approved as a new treatment in CML. It is used as second-line therapy in the case of disease progression or intolerance to first-line treatment. Efficacy is comparable to currently available second-line treatments. 

Alimta maintenance for NSCLC

Alimta now approved as maintenance therapy every 3 weeks after completion of combination therapy with cisplatin for locally advanced or metastatic non-squamous non-small cell lung cancer.

Abraxane now approved for NSCLC

The FDA has approved Abraxane (nanoparticle albumin bound paclitaxel) for the first-line treatment of locally advanced or metastatic non-small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy. 

Yervoy for advanced melanoma

Yervoy (ipilimumab) is now being used for advanced, metastatic malignant melanoma.  Cancer cells can turn off the body's anti-cancer defenses.  Yervoy is an antibody used to keep this from happening.

Zelboraf for melanoma

Zelboraf (vemurafenib) is a new drug for the treatment of unresectable or metastatic melanoma with a specific gene mutation called BRAF V600E.

New Vincristine for ALL

Liposomal vincristine received accelerated FDA approval for the treatment of adult patients with Philadelphia chromosome (Ph)-negative ALL (acute lymphocytic leukemia) in second or greater relapse that have progressed after 2 or more lines of antileukemic therapy.  This preparation of vincristine has less neurologic toxicity than traditional vincristine.

Stivarga for metastatic colon cancer now approved

FDA has approved Stivarga (regorafenib) oral tablets for the treatment of patients with metastatic colorectal cancer who have been previously treated with multiple other therapies.  Stivarga inhibits multiple cellular pathways involved in tumor growth. 


 http://www.chemotherapyadvisor.com/stivarga-approved-for-metastatic-colorectal-cancer/article/261202/?DCMP=EMC-CTA_weekly&spMailingID=4866344&spUserID=MjMyNTIwMzY2OQS2&spJobID=54425681&spReportId=NTQ0MjU2ODES1